{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "3d341272-4993-4503-ac3e-f2e25eaecbd1",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import datacompy"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "259634b1-979e-4fc2-abea-0946c77ebed8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DataComPy Comparison\n",
      "--------------------\n",
      "\n",
      "DataFrame Summary\n",
      "-----------------\n",
      "\n",
      "  DataFrame  Columns  Rows\n",
      "0   Nicolas       13  1005\n",
      "1      John       13   892\n",
      "\n",
      "Column Summary\n",
      "--------------\n",
      "\n",
      "Number of columns in common: 13\n",
      "Number of columns in Nicolas but not in John: 0 []\n",
      "Number of columns in John but not in Nicolas: 0 []\n",
      "\n",
      "Row Summary\n",
      "-----------\n",
      "\n",
      "Matched on: document_number\n",
      "Any duplicates on match values: Yes\n",
      "Absolute Tolerance: 0\n",
      "Relative Tolerance: 0\n",
      "Number of rows in common: 861\n",
      "Number of rows in Nicolas but not in John: 144\n",
      "Number of rows in John but not in Nicolas: 31\n",
      "\n",
      "Number of rows with some compared columns unequal: 861\n",
      "Number of rows with all compared columns equal: 0\n",
      "\n",
      "Column Comparison\n",
      "-----------------\n",
      "\n",
      "Number of columns compared with some values unequal: 11\n",
      "Number of columns compared with all values equal: 2\n",
      "Total number of values which compare unequal: 5,719\n",
      "\n",
      "Columns with Unequal Values or Types\n",
      "------------------------------------\n",
      "\n",
      "                 Column Nicolas dtype John dtype  # Unequal      Max Diff  # Null Diff\n",
      "9       application no.        object     object        745  0.000000e+00           20\n",
      "8         approval date        object     object         12  0.000000e+00            5\n",
      "5        approval phase       float64    float64         23  5.461700e+07           10\n",
      "2               company        object     object        860  0.000000e+00            0\n",
      "6   ind/ide filing date        object     object        589  0.000000e+00          542\n",
      "7   nda/pma filing date        object     object        858  0.000000e+00          734\n",
      "10         pat term ext        object    float64        861  0.000000e+00          306\n",
      "1            patent no.        object     object        846  0.000000e+00          261\n",
      "0          product name        object     object        861  0.000000e+00          643\n",
      "3        reg rev period       float64    float64         50  4.680000e+14            1\n",
      "4         testing phase       float64    float64         14  8.340900e+08            2\n",
      "\n",
      "Sample Rows with Unequal Values\n",
      "-------------------------------\n",
      "\n",
      "  document_number                    product name (Nicolas)                                              product name (John)\n",
      "0         E6-9899                                    CIALIS                                                CIALIS (tadalafil\n",
      "1      2021-12189                                  SARCLISA                                                              NaN\n",
      "2      2015-09521                                   FLUBLOK                                                              NaN\n",
      "3      2021-14461                                 BARHEMSYS                                                              NaN\n",
      "4      2021-12192                                 OPTIMIZER                                                              NaN\n",
      "5      2015-10999  the ISTENT TRABECULAR MICRO-BYPASS STENT                                                              NaN\n",
      "6      2010-14814                                  BYSTOLIC                                BYSTOLIC (nebivolol hydrochloride\n",
      "7         00-1867                      Arava® (leflunomide)  Arava\\n                    ®\\n                     (leflunomide\n",
      "8      2018-03170                                 ZONTIVITY                                                              NaN\n",
      "9      2020-15011                                   CARTIVA                                                              NaN\n",
      "\n",
      "  document_number                                                 patent no. (Nicolas) patent no. (John)\n",
      "0      2024-04479                                                              8198242         8,198,242\n",
      "1      2021-23386                                                  8071643 and 8153689               NaN\n",
      "2          Apr-59                                          5962468 5776944 and 5633262               NaN\n",
      "3      2023-26989                                                              9265740         9,265,740\n",
      "4      2014-10904                                                              5407914         5,407,914\n",
      "5       2011-6162                                                              4977138         4,977,138\n",
      "6      2022-18753                                              8,912,210 and 9,833,448               NaN\n",
      "7      2024-04224  8,008,264; 8,318,682; 9,724,360; 9,949,994; 10,065,958; and RE46762               NaN\n",
      "8      2024-04217                                                              9586955         9,586,955\n",
      "9      2019-26327                                                  7534595 and 7537923               NaN\n",
      "\n",
      "  document_number                                       company (Nicolas)                                                                                                                                                                                                                                       company (John)\n",
      "0         00-2243                            American Home Products Corp.                                                                                                                                                                                                                          American Home Products Corp\n",
      "1      2024-21847                         Santen Pharmaceutical Co., Ltd.                                                                                                                                                                                                                             Santen Pharmaceutical Co\n",
      "2      2015-32247                                        ThromboGenics NV                                                                                                                     ThromboGenics NV, and the USPTO requested FDA's assistance in determining these patents' eligibility for patent term restoration\n",
      "3      2024-14532  The Board of Regents of the University of Texas System  The Board of Regents of \\n                    \\n\\n      ( print page 54834)\\n    \\n                    the University of Texas System, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration\n",
      "4        E6-15555                                         Genentech, Inc.                                                                                                                                                                                                                                       Genentech, Inc\n",
      "5      2014-11925                           Agouron Pharmaceuticals, Inc.                                                                                                                                                                                                                         Agouron Pharmaceuticals, Inc\n",
      "6          Jun-00                               American Cyanamid Company                                                                                       American Cyanamid Company, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration\n",
      "7      2018-02582                                          AcuFocus, Inc.                                                                                                                                                                                                                                        AcuFocus, Inc\n",
      "8          Mar-94                              IDEC Pharmaceuticals Corp.                                                                                                                                                                                                                            IDEC Pharmaceuticals Corp\n",
      "9      2022-15823                         Alkermes Pharma Ireland Limited                                                                                                        Alkermes Pharma Ireland Limited, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration\n",
      "\n",
      "  document_number  reg rev period (Nicolas)  reg rev period (John)\n",
      "0      2014-07058                    2102.0           1.321020e+05\n",
      "1          Feb-83                       7.0           1.917000e+03\n",
      "2      2023-26363                    4361.0           2.098174e+09\n",
      "3        02-17781                      10.0           3.401000e+03\n",
      "4      2023-26299                    2412.0           4.524120e+05\n",
      "5      2023-06580                    4081.0           6.408100e+04\n",
      "6      2014-07329                    1704.0           1.001704e+06\n",
      "7      2016-29303                    2662.0           9.266200e+04\n",
      "8      2014-07336                       3.0           1.704000e+03\n",
      "9      2015-11000                    4959.0           2.627350e+08\n",
      "\n",
      "  document_number  testing phase (Nicolas)  testing phase (John)\n",
      "0      2023-25489                   1727.0                   NaN\n",
      "1          26-Feb                   2249.0                 593.0\n",
      "2      2023-26261                   2441.0           834092441.0\n",
      "3      2010-31074                    285.0                   NaN\n",
      "4      2014-07336                   1704.0                1650.0\n",
      "5      2017-25703                   3845.0                3479.0\n",
      "6      2020-20040                   3727.0                3123.0\n",
      "7        E7-10602                   4720.0                4674.0\n",
      "8        02-17781                   3401.0                2818.0\n",
      "9          Feb-83                   1917.0                1435.0\n",
      "\n",
      "  document_number  approval phase (Nicolas)  approval phase (John)\n",
      "0      2023-17259                     274.0             54617274.0\n",
      "1         E6-9817                     305.0                    NaN\n",
      "2        04-15301                      34.0                    NaN\n",
      "3          26-Feb                     593.0                 1656.0\n",
      "4      2010-31074                     284.0                  285.0\n",
      "5        E6-12572                    3362.0                    NaN\n",
      "6        02-17781                    2818.0                  583.0\n",
      "7      2017-25703                    3479.0                  366.0\n",
      "8      2018-01655                    1558.0                  178.0\n",
      "9      2018-01891                     959.0                  411.0\n",
      "\n",
      "  document_number ind/ide filing date (Nicolas) ind/ide filing date (John)\n",
      "0      2024-20148                    10/28/2009                        NaN\n",
      "1      2024-03028                     7/28/2006                        NaN\n",
      "2      2024-03029                      6/5/2013                        NaN\n",
      "3      2020-19085                    10/30/2020                        NaN\n",
      "4      2016-12823                      5/7/2003                        NaN\n",
      "5      2023-26358                     9/12/2009                        NaN\n",
      "6      2017-16516                     8/31/2000                        NaN\n",
      "7         E6-3641                      4/6/2004                        NaN\n",
      "8      2015-11003                     8/12/2002                        NaN\n",
      "9         00-1871                      7/1/1994                        NaN\n",
      "\n",
      "  document_number nda/pma filing date (Nicolas) nda/pma filing date (John)\n",
      "0      2011-10379                     4/25/2008                        NaN\n",
      "1      2015-31401                      8/8/2009                        NaN\n",
      "2      2024-20148                    12/19/2016                        NaN\n",
      "3         02-1320                     1/21/1990                        NaN\n",
      "4      2022-14430                     1/18/2008                        NaN\n",
      "5         00-1871                     6/24/1998                        NaN\n",
      "6      2021-06709                     9/28/2021                        NaN\n",
      "7      2014-11175                     9/27/2011                        NaN\n",
      "8      2023-02452                     2/25/2015                        NaN\n",
      "9      2018-28216                    11/19/1998                        NaN\n",
      "\n",
      "  document_number approval date (Nicolas)                                                                                                                                                             approval date (John)\n",
      "0      2022-24457               3/10/2020                      November 21, 2019, and that the date of issuance of the interim final rule controlling the drug under section 201(j) of the Controlled Substances Act (21 U\n",
      "1      2021-25297               6/17/2019                                               March 20, 2019, and that the Drug Enforcement Administration issued an interim final rule controlling the product on June 17, 2019\n",
      "2      2024-21836                4/7/2022                                                                                                                                                                              NaN\n",
      "3      2023-26246                5/7/2021    March 2, 2021; however, the Drug Enforcement Agency issued an interim final rule controlling the product under section 201(j) of the Controlled Substances Act on May 7, 2021\n",
      "4      2024-20549                6/1/2022  March 18, 2022, and that the Drug Enforcement Agency issued an interim final rule controlling the product under section 201(j) of the Controlled Substances Act on June 1, 2022\n",
      "5      2016-14357              11/14/2012                                                                                                                                                                       11/15/2012\n",
      "6      2023-26253              10/30/2020               August 7, 2020, and the date of issuance of the interim final rule controlling the drug under section 201(j) of the Controlled Substances Act was October 30, 2020\n",
      "7      2023-25489              12/18/2018                                                                                                                                                                              NaN\n",
      "8      2010-30995               8/21/2009                                                                                                                                                                              NaN\n",
      "9      2022-19714              10/11/2019                                          October 11, 2019, and that the Drug Enforcement Administration issued an interim final rule controlling the product on January 31, 2020\n",
      "\n",
      "  document_number application no. (Nicolas)                                                                                                                                                                                                                             application no. (John)\n",
      "0        E9-21100                NDA 22-304                                                                                                                                                                                 the date the investigational new drug application became effective\n",
      "1      2021-12192                PMA 180036  the date the investigational device exemption for human tests to begin, as required under section 520(g) of the FD&C Act, became effective May 6, 2004.\\n                \\n\\n                    2. \\n                    The date an application\n",
      "2      2024-04203               BLA B761123                                                                                                                                                                                 the date the investigational new drug application became effective\n",
      "3      2015-11003                 NADA 141-                                                                                                                                                                                                                                       NADA 141-339\n",
      "4      2023-06580                PMA 170036                                                                                                                                                            the premarket approval application (PMA) for M6-C ARTIFICIAL CERVICAL DISC (PMA 170036)\n",
      "5        02-13227               BLA 98-0286                                                                                                                                                                                 the date the investigational new drug application became effective\n",
      "6      2024-14577                BLA 761224                                                                                                                                                                                 the date the investigational new drug application became effective\n",
      "7      2022-14930                BLA 761149                                                                                                                                                                                                                                                NaN\n",
      "8         E7-9733                NDA 21-399                                                                                                                                                                                 the date the investigational new drug application became effective\n",
      "9      2020-20104                BLA 761090                                                                                                                                                                                  the biologics license application (BLA) for TAKHZYRO (BLA 761090)\n",
      "\n",
      "  document_number pat term ext (Nicolas)  pat term ext (John)\n",
      "0        03-29333                   1397               1397.0\n",
      "1        01-12093                   1824               1824.0\n",
      "2      2018-26035                    298                298.0\n",
      "3      2011-15692                    959                  NaN\n",
      "4          Apr-59                    659                  NaN\n",
      "5        E9-23900                   1826               1826.0\n",
      "6      2020-04363                   1244                  NaN\n",
      "7      2023-26885                   1516               1516.0\n",
      "8      2010-21583                    896                896.0\n",
      "9        01-17103                   1255               1255.0\n",
      "\n",
      "Sample Rows Only in Nicolas (First 10 Columns)\n",
      "----------------------------------------------\n",
      "\n",
      "   index document_number          product name patent no.                                                    company  reg rev period  testing phase  approval phase ind/ide filing date nda/pma filing date\n",
      "0   64.0        96-13535        PRECOSE<SUP>TM    4904769                                                   Bayer AG          5647.0         3789.0          1858.0           3/23/1980           3/23/1980\n",
      "1   87.0         97-2064  DIFFERIN Topical Gel    5212303  Centre International de Recherches Dermatologiques (CIRD)          2447.0         1401.0          1046.0           9/20/1989           9/20/1989\n",
      "2   69.0        96-21849    ARIMIDEX<Register>    4935437                                                Zeneca Ltd.          1336.0         1062.0           274.0            5/2/1992            5/2/1992\n",
      "3  126.0         98-9864       ZAGAM<Register>    4795751                         Dainippon Pharmaceutical Co., Ltd.          2030.0         1671.0           359.0            6/1/1991            6/1/1991\n",
      "4  101.0         97-6977       HYCAMTIN<SUP>TM    5004758                                   SmithKline Beecham Corp.          2644.0         2485.0           159.0            3/4/1989            2/2/1989\n",
      "5   90.0         97-2871  DIFFERIN Topical Gel  Re. 34440  Centre International de Recherches Dermatologiques (CIRD)          2447.0         1401.0          1046.0           9/20/1989           9/20/1989\n",
      "6   66.0        96-20340     DYNABAC<Register>    4048306                                  Boehringer Ingelheim GmbH          2469.0         1687.0           782.0           9/16/1988           9/16/1988\n",
      "7  182.0        99-11821   Aggrastat<Register>    5292756                                                Merck & Co.          2247.0         2051.0           196.0           3/21/1992           3/21/1992\n",
      "8   34.0        95-10073          LUVOX<SUP>TM    4085225                                       Duphar International          6958.0         5886.0          1072.0          11/19/1975          11/19/1975\n",
      "9  145.0        98-21407    Fareston<Register>    4696949                                            ORION-YHTYMA OY          3706.0         2828.0           878.0            4/8/1987            4/8/1987\n",
      "\n",
      "Sample Rows Only in John (First 10 Columns)\n",
      "-------------------------------------------\n",
      "\n",
      "   index document_number                                                                                     product name patent no.                             company  reg rev period  testing phase  approval phase ind/ide filing date nda/pma filing date\n",
      "0  445.0         E9-4770                                                                              ARRANON (nelarabine  5,424,295            ,SmithKline Beecham Corp    4.163000e+03         3980.0           183.0            6/7/1994           4/29/2005\n",
      "1  210.0          13-Jan  Aciphex\\n                    TM\\n                    \\n                     (rabeprazole sodium  5,045,552                            Eisai Co    2.922000e+03         2415.0           507.0           8/21/1991                 NaN\n",
      "2  595.0      2014-25032                                                                                              NaN        NaN                 Durant Wayland, Inc    1.950000e+03            NaN             NaN                 NaN                 NaN\n",
      "3  209.0          01-974                                                                                              NaN  5,099,013                      Biomatrix, Inc    2.050000e+12         1783.0          1166.0                 NaN                 NaN\n",
      "4  242.0          Feb-65                                                                                              NaN  4,968,514                      BF Goodrich Co    1.326000e+03          739.0             NaN                 NaN                 NaN\n",
      "5  711.0      2017-25780                                                                                              NaN        NaN                        Ajinomoto Co    4.967000e+03         3091.0          1876.0                 NaN                 NaN\n",
      "6  625.0      2015-31097                                                                                              NaN  7,323,195           Napo Pharmaceuticals, Inc    7.784000e+03         7391.0           393.0                 NaN                 NaN\n",
      "7  639.0      2016-08338                                                                                              NaN        NaN                      Genentech, Inc    1.698000e+03         1504.0           194.0           3/11/2009                 NaN\n",
      "8  202.0         00-2032                                                                                              NaN  4,834,757                  DePuy AcroMed, Inc    2.631000e+03         1708.0           923.0                 NaN                 NaN\n",
      "9  626.0      2015-31095                                                                                              NaN  7,668,599  Second Sight Medical Products, Inc    2.282000e+03         1630.0           652.0                 NaN                 NaN\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# 1. load data\n",
    "df1 = pd.read_csv('results_nicolas_all.csv')\n",
    "df2 = pd.read_csv('Results_John_all.csv')\n",
    "\n",
    "# 2. synchronize columns for comparison\n",
    "df2.rename(columns={'document_id': 'document_number'},inplace=True)\n",
    "df1=df1[['document_number','Product Name', 'Patent No.', 'Company', 'Reg Rev Period',\n",
    "       'Testing Phase', 'Approval Phase', 'IND/IDE Filing Date',\n",
    "       'NDA/PMA Filing Date', 'Approval Date', 'Application No.',\n",
    "       'Pat Term Ext']]\n",
    "df1.columns = df1.columns.str.upper()\n",
    "df2.columns = df2.columns.str.upper()\n",
    "\n",
    "# 3. restrict comparison to all entries that are not NaN\n",
    "common_document_numbers = set(df1['DOCUMENT_NUMBER']).intersection(df2['DOCUMENT_NUMBER'])\n",
    "df1 = df1[df1['DOCUMENT_NUMBER'].isin(common_document_numbers) & df1['COMPANY'].notna()]\n",
    "df2 = df2[df2['DOCUMENT_NUMBER'].isin(common_document_numbers) & df2['COMPANY'].notna()]\n",
    "\n",
    "# 4. compare differences\n",
    "compare = datacompy.Compare(\n",
    "    df1.reset_index(),\n",
    "    df2.reset_index(),\n",
    "    join_columns='DOCUMENT_NUMBER',\n",
    "    df1_name='Nicolas',\n",
    "    df2_name='John'\n",
    ")\n",
    "print(compare.report())"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
